Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434042 | 0.94 | MAPT (0.38) | MAPTCYP2C9EGFRALDH1A1NPC1 | |
| SCHEMBL23567967 | 0.87 | EGFR (0.37) | MAPTEGFRALDH1A1NPC1PLA2G1B | |
| SCHEMBL17308140 | 0.87 | CYP2C19 (0.38) | EGFRALDH1A1NPC1PLA2G1BNFKB1 | |
| SCHEMBL26197278 | 0.85 | EGFR (0.36) | MAPTCYP2C9EGFRALDH1A1NPC1 | |
| SCHEMBL21884000 | 0.85 | MEN1 (0.44) | MAPTCYP2C9EGFRALDH1A1NPC1 | |
| SCHEMBL9979772 | 0.83 | MAPT (0.38) | MAPTCYP2C9EGFRALDH1A1NPC1 | |
| SCHEMBL20546635 | 0.82 | EPHX2 (0.36) | EGFRALDH1A1NPC1PLA2G1BNFKB1 | |
| SCHEMBL29806306 | 0.82 | EPHX2 (0.36) | EGFRALDH1A1NPC1PLA2G1BNFKB1 | |
| SCHEMBL23567965 | 0.79 | EGFR (0.39) | MAPTEGFRALDH1A1NPC1PLA2G1B | |
| SCHEMBL13434043 | 0.78 | ALDH1A1 (0.45) | ALDH1A1POLBKMT2AMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357828-B2 | Releasable GLP-1 conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-06-14 | — | — | US | disclosed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| WO-2021127461-A1 | METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID | XW LABORATORIES LIMITED (CN) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020053815-A1 | RELEASABLE GLP-1 CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2020-03-19 | — | — | WO | disclosed |
| US-20150346170-A1 | Extraction, Derivatization, and Quantification of Analytes | QUANTALYTICAL LABS INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150346170-A1 | Extraction, Derivatization, and Quantification of Analytes | QUANTALYTICAL LABS INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | MAPT 2695/4885CYP2C9 4085/4885EGFR 298/4885 |
| US-11357828-B2 | Releasable GLP-1 conjugates | GLP1R, GIPR, IAPP | MAPT 3972/4885CYP2C9 1961/4885EGFR 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.